Patents by Inventor Wayne C. Drevets
Wayne C. Drevets has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250134859Abstract: The disclosure provides methods for treating major depressive disorder in a human patient having moderate or severe anhedonia. The methods comprise administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient had an inadequate response to other antidepressant therapy prior to treatment with aticaprant. In other embodiments, the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.Type: ApplicationFiled: November 25, 2024Publication date: May 1, 2025Inventors: Mark Schmidt, Vanina Popova, Adam Savitz, Rama Melkote, Wayne C. Drevets, Srihari Gopal, Darrel Pemberton, Chakradhar Lagishetty, Iva Kezic
-
Publication number: 20250090482Abstract: The disclosure provides methods for treating depression comprising intranasally administering to a patient in need thereof an effective amount of esketamine, wherein the patient is identified as biomarker signature positive, and wherein the patient is identified as biomarker signature positive if a biological sample obtained from the patient is identified as having a level of at least one biomarker that is greater or less than a reference biomarker level.Type: ApplicationFiled: January 9, 2023Publication date: March 20, 2025Inventors: Wayne C. DREVETS, Hartmuth Christian KOLB, Ziad Serhal SAAD
-
Publication number: 20250064779Abstract: The disclosure provides methods for treating major depressive disorder in a human patient, wherein the patient is identified as biomarker signature positive. The methods comprise administering to the patient in need thereof an effective amount of an antidepressant.Type: ApplicationFiled: January 9, 2023Publication date: February 27, 2025Inventors: Wayne C. DREVETS, Hartmuth Christian KOLB, Ziad Serhal SAAD
-
Patent number: 12201610Abstract: The present disclosure relates to compositions, including oral compositions in the form of tablets, comprising aticaprant and methods of using the same.Type: GrantFiled: March 27, 2024Date of Patent: January 21, 2025Assignee: Janssen Pharmaceuticals, Inc.Inventors: Nicolaas Martha Felix Goyvaerts, Mark Schmidt, Vanina Popova, Adam Savitz, Rama Melkote, Wayne C. Drevets, Srihari Gopal, Darrel Pemberton, Chakradhar Lagishetty, Iva Kezic, Mahesh N. Samtani, Tom Huybrechts, Geert Van der Avoort, Matthieu Ravelingien, Laura Martinez Marcos, Tatiana Marcozzi, Katarina Jokicevic
-
Patent number: 12201634Abstract: The present disclosure is directed to, inter alia, methods of treating a subject suffering from or diagnosed with depression, comprising administering to a subject in need of such treatment an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 to R4 are described herein and wherein the compound is administered prior to sleep.Type: GrantFiled: December 15, 2021Date of Patent: January 21, 2025Assignee: Janssen Pharmaceutica NVInventors: Peter De Boer, Justine M. Kent, Wayne C. Drevets
-
Patent number: 12171743Abstract: The disclosure provides crystalline and amorphous forms of aticaprant. Also provided by the disclosure are pharmaceutical compositions comprising the amorphous or crystalline forms, methods of treating major depressive disorder using the amorphous or crystalline forms of aticaprant, amorphous or crystalline forms of aticaprant for use in the treatment of major depressive disorder in a human patient having anhedonia, uses of the amorphous or crystalline forms of aticaprant in the manufacture of a medicament for the treatment of major depressive disorder, and packages or pharmaceutical products comprising (i) amorphous or crystalline forms of aticaprant and (ii) instructions for treating major depressive disorder. In some aspects, the human patient treated as described herein has anhedonia.Type: GrantFiled: May 31, 2024Date of Patent: December 24, 2024Assignee: Janssen Pharmaceuticals, Inc.Inventors: Philippe Fernandes, Mark Schmidt, Vanina Popova, Adam Savitz, Rama Melkote, Wayne C. Drevets, Srihari Gopal, Darrel Pemberton, Chakradhar Lagishetty, Iva Kezic
-
Patent number: 12161622Abstract: The disclosure provides methods for treating major depressive disorder in a human patient having moderate or severe anhedonia. The methods comprise administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient had an inadequate response to other antidepressant therapy prior to treatment with aticaprant. In other embodiments, the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.Type: GrantFiled: February 11, 2022Date of Patent: December 10, 2024Assignee: Janssen Pharmaceuticals, Inc.Inventors: Mark Schmidt, Vanina Popova, Adam Savitz, Rama Melkote, Wayne C. Drevets, Srihari Gopal, Darrel Pemberton, Chakradhar Lagishetty, Iva Kezic
-
Patent number: 12150929Abstract: The disclosure provides methods for treating major depressive disorder in a human patient having moderate or severe anhedonia. The methods comprise administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient had an inadequate response to other antidepressant therapy prior to treatment with aticaprant. In other embodiments, the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.Type: GrantFiled: January 31, 2024Date of Patent: November 26, 2024Assignee: Janssen Pharmaceuticals, Inc.Inventors: Mark Schmidt, Vanina Popova, Adam Savitz, Rama Melkote, Wayne C. Drevets, Srihari Gopal, Darrel Pemberton, Chakradhar Lagishetty, Iva Kezic
-
Publication number: 20240316003Abstract: The disclosure provides crystalline and amorphous forms of aticaprant. Also provided by the disclosure are pharmaceutical compositions comprising the amorphous or crystalline forms, methods of treating major depressive disorder using the amorphous or crystalline forms of aticaprant, amorphous or crystalline forms of aticaprant for use in the treatment of major depressive disorder in a human patient having anhedonia, uses of the amorphous or crystalline forms of aticaprant in the manufacture of a medicament for the treatment of major depressive disorder, and packages or pharmaceutical products comprising (i) amorphous or crystalline forms of aticaprant and (ii) instructions for treating major depressive disorder. In some aspects, the human patient treated as described herein has anhedonia.Type: ApplicationFiled: May 31, 2024Publication date: September 26, 2024Inventors: Philippe Fernandes, Mark Schmidt, Vanina Popova, Adam Savitz, Rama Melkote, Wayne C. Drevets, Srihari Gopal, Darrel Pemberton, Chakradhar Lagishetty, Iva Kezic
-
Publication number: 20240269110Abstract: The present disclosure relates to compositions, including oral compositions in the form of tablets, comprising aticaprant and methods of using the same.Type: ApplicationFiled: March 27, 2024Publication date: August 15, 2024Inventors: Nicolaas Martha Felix Goyvaerts, Mark Schmidt, Vanina Popova, Adam Savitz, Rama Melkote, Wayne C. Drevets, Srihari Gopal, Darrel Pemberton, Chakradhar Lagishetty, Iva Kezic, Mahesh N. Samtani, Tom Huybrechts, Geert Van der Avoort, Matthieu Ravelingien, Laura Martinez Marcos, Tatiana Marcozzi, Katarina Jokicevic
-
Publication number: 20240238245Abstract: The disclosure provides methods for treating major depressive disorder in a human patient having moderate or severe anhedonia. The methods comprise administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient had an inadequate response to other antidepressant therapy prior to treatment with aticaprant. In other embodiments, the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.Type: ApplicationFiled: May 3, 2022Publication date: July 18, 2024Inventors: Mark SCHMIDT, Vanina POPOVA, Adam SAVITZ, Rama MELKOTE, Wayne C. DREVETS, Srihari GOPAL, Darrel PEMBERTON, Chakradhar LAGISHETTY, Iva KEZIC
-
Publication number: 20240189274Abstract: The disclosure provides methods for treating major depressive disorder in a human patient having moderate or severe anhedonia. The methods comprise administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient had an inadequate response to other antidepressant therapy prior to treatment with aticaprant. In other embodiments, the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.Type: ApplicationFiled: January 31, 2024Publication date: June 13, 2024Inventors: Mark Schmidt, Vanina Popova, Adam Savitz, Rama Melkote, Wayne C. Drevets, Srihari Gopal, Darrel Pemberton, Chakradhar Lagishetty, Iva Kezic
-
Patent number: 11998525Abstract: The disclosure provides methods for treating major depressive disorder in a human patient having moderate or severe anhedonia. The methods comprise administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient had an inadequate response to other antidepressant therapy prior to treatment with aticaprant. In other embodiments, the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.Type: GrantFiled: March 23, 2023Date of Patent: June 4, 2024Assignee: Janssen Pharmaceuticals, Inc.Inventors: Mark Schmidt, Vanina Popova, Adam Savitz, Rama Melkote, Wayne C. Drevets, Srihari Gopal, Darrel Pemberton, Chakradhar Lagishetty, Iva Kezic
-
Patent number: 11998524Abstract: The disclosure provides crystalline and amorphous forms of aticaprant. Also provided by the disclosure are pharmaceutical compositions comprising the amorphous or crystalline forms, methods of treating major depressive disorder using the amorphous or crystalline forms of aticaprant, amorphous or crystalline forms of aticaprant for use in the treatment of major depressive disorder in a human patient having anhedonia, uses of the amorphous or crystalline forms of aticaprant in the manufacture of a medicament for the treatment of major depressive disorder, and packages or pharmaceutical products comprising (i) amorphous or crystalline forms of aticaprant and (ii) instructions for treating major depressive disorder. In some aspects, the human patient treated as described herein has anhedonia.Type: GrantFiled: March 6, 2023Date of Patent: June 4, 2024Assignee: Janssen Pharmaceuticals, Inc.Inventors: Philippe Fernandes, Mark Schmidt, Vanina Popova, Adam Savitz, Rama Melkote, Wayne C. Drevets, Srihari Gopal, Darrel Pemberton, Chakradhar Lagishetty, Iva Kezic
-
Publication number: 20230348377Abstract: The disclosure provides compositions containing pure aticaprant, solvates of aticaprant, and methods of treating major depressive disorder using aticaprant.Type: ApplicationFiled: March 6, 2023Publication date: November 2, 2023Inventors: Riccardo Surmont, Mark Schmidt, Vanina Popova, Adam Savitz, Rama Melkote, Wayne C. Drevets, Srihari Gopal, Darrel Pemberton, Chakradhar Lagishetty, Iva Kezic
-
Publication number: 20230277500Abstract: The present disclosure relates to compositions, including oral compositions in the form of tablets, comprising aticaprant and methods of using the same.Type: ApplicationFiled: March 6, 2023Publication date: September 7, 2023Inventors: Nicolaas Martha Felix Goyvaerts, Mark Schmidt, Vanina Popova, Adam Savitz, Rama Melkote, Wayne C. Drevets, Srihari Gopal, Darrel Pemberton, Chakradhar Lagishetty, Iva Kezic, Mahesh N. Samtani, Tom Huybrechts, Geert Van der Avoort, Matthieu Ravelingien, Laura Martinez Marcos, Tatiana Marcozzi, Katarina Jokicevic
-
Publication number: 20230277499Abstract: The disclosure provides crystalline and amorphous forms of aticaprant. Also provided by the disclosure are pharmaceutical compositions comprising the amorphous or crystalline forms, methods of treating major depressive disorder using the amorphous or crystalline forms of aticaprant, amorphous or crystalline forms of aticaprant for use in the treatment of major depressive disorder in a human patient having anhedonia, uses of the amorphous or crystalline forms of aticaprant in the manufacture of a medicament for the treatment of major depressive disorder, and packages or pharmaceutical products comprising (i) amorphous or crystalline forms of aticaprant and (ii) instructions for treating major depressive disorder. In some aspects, the human patient treated as described herein has anhedonia.Type: ApplicationFiled: March 6, 2023Publication date: September 7, 2023Inventors: Philippe Fernandes, Mark Schmidt, Vanina Popova, Adam Savitz, Rama Melkote, Wayne C. Drevets, Srihari Gopal, Darrel Pemberton, Chakradhar Lagishetty, Iva Kezic
-
Publication number: 20230233525Abstract: The disclosure provides methods for treating major depressive disorder in a human patient having moderate or severe anhedonia. The methods comprise administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient had an inadequate response to other antidepressant therapy prior to treatment with aticaprant. In other embodiments, the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.Type: ApplicationFiled: March 23, 2023Publication date: July 27, 2023Inventors: Mark Schmidt, Vanina Popova, Adam Savitz, Rama Melkote, Wayne C. Drevets, Srihari Gopal, Darrel Pemberton, Chakradhar Lagishetty, Iva Kezic
-
Publication number: 20230089113Abstract: The present invention is directed to methods and dosing regimens for the treatment of depression (preferably, treatment resistant depression), for the treatment of depression in a suicidal patient, and/or for the treatment and/or prevention of suicidality (e.g. suicidal ideations).Type: ApplicationFiled: April 22, 2022Publication date: March 23, 2023Inventors: Lodewijk Ivo Caers, Jaskaran Singh, Peter Nicholas Zannikos, Wayne C. Drevets, Ella Daly, Carla Maria Canuso, Margaret Fedgchin, Frank Wiegand, Giacomo Salvadore
-
Publication number: 20220370409Abstract: The disclosure provides methods for treating major depressive disorder in a human patient having moderate or severe anhedonia. The methods comprise administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient had an inadequate response to other antidepressant therapy prior to treatment with aticaprant. In other embodiments, the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.Type: ApplicationFiled: February 11, 2022Publication date: November 24, 2022Inventors: Mark Schmidt, Vanina Popova, Adam Savitz, Rama Melkote, Wayne C. Drevets, Srihari Gopal, Darrel Pemberton, Chakradhar Lagishetty, Iva Kezic